cefprozil(redirected from Cefproxil)
Also found in: Wikipedia.
Apo-Cefprozil, Cefzil, Ran-Cefprozil, Sandoz Cefprozil
Pharmacologic class: Second-generation cephalosporin
Therapeutic class: Anti-infective
Pregnancy risk category B
Interferes with bacterial cell-wall synthesis and division by binding to cell wall, causing cell to die. Active against gram-negative and gram-positive bacteria, with expanded activity against gram-negative bacteria. Exhibits minimal immunosuppressant activity.
Powder for suspension: 125 mg/5 ml, 250 mg/5 ml
Tablets: 250 mg, 500 mg
⊘Indications and dosages
➣ Uncomplicated skin infections caused by Staphylococcus aureus and Streptococcus pyogenes
Adults and children ages 13 and older: 250 to 500 mg P.O. q 12 hours or 500 mg P.O. daily for 10 days
➣ Pharyngitis or tonsillitis caused by S. pyogenes
Adults and children ages 13 and older: 500 mg P.O. daily for at least 10 days
➣ Acute bronchitis; acute bacterial chronic bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis
Adults and children ages 13 and older: 500 mg P.O. q 12 hours for 10 days
➣ Acute sinusitis caused by S. pneumoniae, H. influenzae, and M. catarrhalis
Adults and children ages 13 and older: 250 mg P.O. q 12 hours for 10 days; for moderate to severe infections, 500 mg P.O. q 12 hours for 10 days
Children ages 6 months to 12 years: 7.5 mg/kg P.O. q 12 hours for 10 days; for moderate to severe infections, 15 mg/kg P.O. q 12 hours for 10 days
➣ Otitis media caused by S. pneumoniae, H. influenzae, and M. catarrhalis
Children ages 6 months to 12 years: 15 mg/kg P.O. q 12 hours for 10 days
• Renal impairment
• Hypersensitivity to cephalosporins or penicillins
• Renal failure
Use cautiously in:
• renal or hepatic impairment
• pregnant or breastfeeding patients
• Obtain specimens for culture and sensitivity testing as necessary before starting therapy.
• Give drug with food.
CNS: headache, dizziness, drowsiness, hyperactivity, hypotonia, insomnia, confusion, seizures
GI: nausea, vomiting, diarrhea, abdominal pain, dyspepsia, pseudomembranous colitis
GU: hematuria, vaginal candidiasis, genital pruritus, renal dysfunction, toxic nephropathy
Hematologic: eosinophilia, aplastic anemia, hemolytic anemia, hemorrhage, bone marrow depression, hypoprothrombinemia
Hepatic: hepatic dysfunction
Skin: toxic epidermal necrolysis, diaper rash, erythema multiforme, Stevens-Johnson syndrome
Other: allergic reactions, carnitine deficiency, drug fever, superinfection, serum sickness-like reaction, anaphylaxis
Drug-drug.Aminoglycosides: increased risk of nephrotoxicity
Antacids containing aluminum or magnesium, histamine2-receptor antagonists: increased cefprozil absorption
Probenecid: decreased excretion and increased blood level of cefprozil
Drug-diagnostic tests.Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, blood urea nitrogen, creatinine, eosinophils, gamma-glutamyltransferase, lactate dehydrogenase, white blood cells in urine: increased levels
Blood glucose, Coombs' test, urine glucose tests using Benedict's solution: false-positive results
Platelets, white blood cells: decreased counts
Drug-food.Moderate- or high-fat meal: increased drug bioavailability
Stay alert for life-threatening reactions, including anaphylaxis, serum sickness-like reaction, Stevens-Johnson syndrome, and pseudomembranous colitis.
• Monitor neurologic status, particularly for signs and symptoms of impending seizures.
• Monitor kidney and liver function test results and assess fluid intake and output.
• Monitor CBC with white cell differential, prothrombin time, and bleeding time. Watch for signs and symptoms of blood dyscrasias, especially hypoprothrombinemia.
• Monitor temperature. Stay alert for signs and symptoms of superinfection.
Advise patient to immediately report rash, bleeding tendency, or CNS changes.
• Teach patient to recognize signs and symptoms of superinfection, and instruct him to report these right away.
• Tell patient to take drug with food.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and foods mentioned above.